Tapinarof
Highest phase reached
Approved
Drug type
Small molecule
First approval year
2022
- First approval year
- 2022
- Listing at source
- Listed
- Highest phase reached
- Approved
- Drug type
- Small molecule
- Drug name
- Tapinarof
- Molecular weight
- 254.33
- Structure (SMILES)
- CC(C)c1c(O)cc(/C=C/c2ccccc2)cc1O
- vtama
- Vtama
- benvitimod
- Benvitimod
- Benvitimod Cream
- gsk 2894512
- GSK-2894512
- gsk2894512
- GSK2894512
- GSK2894512 cream
- GSK2894512 Cream
- GSK2894512 Topical Cream
- tapinarof
- Tapinarof
- Tapinarof [INN]
- Tapinarof [USAN]
- Tapinarof [WHO-DD]
- tapinarof inn
- tapinarof usan
- tapinarof who dd
- vtama
- Vtama
- VTAMA (tapinarof) cream, 1%
- VTAMA®
- VTAMA® (tapinarof) Cream 1%
- Vtama® (Tapinarof) Cream, 1%
- wbi 1001
And 2 more, listed on the interactive page.
- ATC classification codes
- D05AX07
Sources for recorded values
- CAS registry numbers
- 79338-84-4
- ChEMBL ID
- CHEMBL259571
- InChIKey
- ZISJNXNHJRQYJO-CMDGGOBGSA-N
- PubChem compound IDs
- 6439522
- RxNorm IDs (RxCUI)
- 2602286
- FDA ingredient codes (UNII)
- 84HW7D0V04
- Applicant
- ORGANON LLC
- Approval date
- 23 May 2022
- Application number
- NDA215272
- Patents
- 12
- Designations
- 0
- Earliest recorded loss of exclusivity
- 18 Dec 2039
- First in class
- Yes
- Fast track
- No
- Breakthrough designation
- No
- Orphan designation
- No
- Priority review
- No
- Orphan exclusivity
- No
- Accelerated approval
- No
- Availability
- Prescription only
- Pharmacology name
- tapinarof
- Type
- Synthetic organic
- Approval recorded by Guide to Pharmacology
- Yes
Administration routes
- topical
- Action
- Agonist
- Action type
- Agonist
- Target
- aryl hydrocarbon receptor
- Gene symbol
- AHR
- Protein identifier
- P35869
- Affinity units
- pKd
- Primary target
- Yes
- Mechanism
- Aryl hydrocarbon receptor agonist
- Action type
- Agonist
- Target
- Aryl hydrocarbon receptor
- Protein identifier
- P35869
Open Targets mechanisms
- Mechanism
- Aryl hydrocarbon receptor agonist
- Action type
- Agonist
- Target
- Aryl hydrocarbon receptor
- Condition
- Dermatitis, Atopic
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000274
- Subject identifier
- D003876
- Condition
- Psoriasis
- Highest recorded phase
- 4
- Condition identifier
- EFO:0000676
- Subject identifier
- D011565
- Condition identifier
- EFO_0000274
- Condition identifier
- EFO_0000676
- Condition identifier
- EFO_0003834
- Condition identifier
- EFO_1001494
- Condition identifier
- EFO_1001494
- Highest recorded phase
- 4
- Condition identifier
- HP_0000982
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0004980
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0005083
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0005282
- Highest recorded phase
- 1
- NCT01098721
- NCT03956355
- NCT03983980
- NCT04042103
- NCT04053387
- NCT05064748
- NCT05172726
- NCT05789576
- NCT05981118
- NCT06103695
- NCT05014568
- NCT05032859
- NCT05142774
- NCT05186805
- NCT05326672
- Route
- Topical
- How often
- Once daily
- Apply a thin layer to affected areas
- Not for oral, ophthalmic, or intravaginal use
- Wash hands after application unless for hands use
- Hydrogen bond acceptors
- 2
- Hydrogen bond donors
- 2
- Polar surface area
- 40.46
- Calculated partition coefficient (ALogP)
- 4.39
- Calculated partition coefficient (XLogP)
- 4.6
- Prodrug
- No
- Chirality
- Achiral
- Inorganic
- No
- Rule-of-five violations
- 0
- Rotatable bonds
- 3
- Heavy atoms
- 19
- Molecular formula
- C17H18O2
- Monoisotopic mass
- 254.130679813
- Natural product
- Yes
- 81672-5051
- Recorded assays
- 27
- Active assays
- 6
Active assay types
- Confirmatory
- Dermatologic Agents
Related records
Trials (35)
- A Dose-Finding Study of GSK2894512 Cream in Subjects With Atopic Dermatitis (AD)
- A Dose-Finding Study of GSK2894512 Cream in Subjects With Plaque Psoriasis
- A Safety/Efficacy Study of a Non-steroid, Topical Cream Treatment of Psoriasis Over 12-weeks
- A Single Dose Phase I Exploratory Study in Healthy Volunteers With GSK2894512 Cream
- A Study Comparing Tapinarof Cream 1% and Vtama® Cream 1% in the Treatment of Plaque Psoriasis.
- A Study to Evaluate Pharmacokinetic (PK), Safety and Tolerability of GSK2894512 in Healthy Adult Subjects
- A Study to Evaluate the Irritation Potential of GSK2894512 Cream on Skin in Healthy Subjects
- A Study to Investigate Efficacy and Safety of VTAMA (Tapinarof) Cream, 1% in Intertriginous Plaque Psoriasis
- A Study to Investigate Efficacy and Safety of VTAMA® (Tapinarof) Cream, 1% in Plaque Psoriasis in the Head and Neck Region
- A Study to Investigate Safety and Efficacy of Tapinarof Cream, 1% in Participants Ages 3 Months to < 24 Months With Atopic Dermatitis
- Comparison of Post-Inflammatory Pigment Alteration After Psoriasis Treatment (PIPA - Dermavant)
- Efficacy and Safety of Benvitimod Cream in Cutaneous T-Cell Lymphoma
- Efficacy and Safety of Benvitimod Cream in the Retreatment of Mild to Moderate Psoriasis
- Efficacy of Topical Tapinarof Versus Betamethasone in the Treatment of Plaque Psoriasis
- GSK2894512 Vehicle-Controlled Study for Adult Plaque Psoriasis
- Long Term Extension Study of Tapinarof Cream, 1% for Subjects With Atopic Dermatitis
- Long Term Extension Study of Tapinarof for Plaque Psoriasis in Adults (3003)
- Maximal Use Study of Tapinarof Cream, 1% in Adults With Extensive Plaque Psoriasis
- Maximal Use Study of Tapinarof Cream, 1% in Pediatric Subjects With Extensive Atopic Dermatitis
- Non-steroid, Atopic Dermatitis Phase IIb 12-week Trial; Topical WBI-1001 Cream
Approved for (1)
In development for (1)
- Atopic eczema Phase 3
Other linked conditions (1)
Targets (1)
- AHR Aryl hydrocarbon receptor agonist